Indolent Lymphoma - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 173 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Indolent Lymphoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Indolent Lymphoma - Pipeline Review, H1 2015', provides an overview of the Indolent Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Indolent Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Indolent Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Indolent Lymphoma - Overview 10
Pipeline Products for Indolent Lymphoma - Comparative Analysis 11
Indolent Lymphoma - Therapeutics under Development by Companies 12
Indolent Lymphoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Unknown Stage Products 17
Indolent Lymphoma - Products under Development by Companies 18
Indolent Lymphoma - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
Astellas Pharma Inc. 21
Bayer AG 22
BioMedics Japan Inc. 23
Biothera, Inc. 24
Boehringer Ingelheim GmbH 25
Celgene Corporation 26
Eagle Pharmaceuticals, Inc. 27
Emergent BioSolutions Inc. 28
F. Hoffmann-La Roche Ltd. 29
Gilead Sciences, Inc. 30
Incyte Corporation 31
Infinity Pharmaceuticals, Inc. 32
Juno Therapeutics Inc. 33
Kite Pharma, Inc. 34
MedImmune, LLC 35
Merck & Co., Inc. 36
Merck KGaA 37
MorphoSys AG 38
Pharmacyclics, Inc. 39
Sandoz Inc. 40
Indolent Lymphoma - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
SAssessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
bendamustine hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bendamustine hydrochloride SI - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BI-836826 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
blinatumomab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BM-ca - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
copanlisib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
DI-B4 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
duvelisib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GS-9973 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ibrutinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
idelalisib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Imprime PGG - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
INCB-050465 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
INCB-39110 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
INCB-40093 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
JCAR-015 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
KTE-C19 CAR - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
lenalidomide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
MEDI-551 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MOR-208 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
obinutuzumab - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
otlertuzumab - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
rituximab biosimilar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
vorinostat - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Indolent Lymphoma - Recent Pipeline Updates 104
Indolent Lymphoma - Dormant Projects 158
Indolent Lymphoma - Discontinued Products 159
Indolent Lymphoma - Product Development Milestones 160
Featured News & Press Releases 160
Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 160
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 160
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 161
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 162
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 164
Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 166
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 167
Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 168
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 169
Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 171
Appendix 172
Methodology 172
Coverage 172
Secondary Research 172
Primary Research 172
Expert Panel Validation 172
Contact Us 172
Disclaimer 173

List of Tables
Number of Products under Development for Indolent Lymphoma, H1 2015 10
Number of Products under Development for Indolent Lymphoma - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Indolent Lymphoma - Pipeline by Amgen Inc., H1 2015 20
Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H1 2015 21
Indolent Lymphoma - Pipeline by Bayer AG, H1 2015 22
Indolent Lymphoma - Pipeline by BioMedics Japan Inc., H1 2015 23
Indolent Lymphoma - Pipeline by Biothera, Inc., H1 2015 24
Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 25
Indolent Lymphoma - Pipeline by Celgene Corporation, H1 2015 26
Indolent Lymphoma - Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 27
Indolent Lymphoma - Pipeline by Emergent BioSolutions Inc., H1 2015 28
Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 29
Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2015 30
Indolent Lymphoma - Pipeline by Incyte Corporation, H1 2015 31
Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 32
Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2015 33
Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H1 2015 34
Indolent Lymphoma - Pipeline by MedImmune, LLC, H1 2015 35
Indolent Lymphoma - Pipeline by Merck & Co., Inc., H1 2015 36
Indolent Lymphoma - Pipeline by Merck KGaA, H1 2015 37
Indolent Lymphoma - Pipeline by MorphoSys AG, H1 2015 38
Indolent Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015 39
Indolent Lymphoma - Pipeline by Sandoz Inc., H1 2015 40
Assessment by Monotherapy Products, H1 2015 41
Number of Products by Stage and Target, H1 2015 43
Number of Products by Stage and Mechanism of Action, H1 2015 45
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 104
Indolent Lymphoma - Dormant Projects, H1 2015 158
Indolent Lymphoma - Discontinued Products, H1 2015 159